10th Italian Meeting on Mitochondrial Diseases

Virtual Meeting

October 9-10, 2020

Mitocon is pleased to announce the 10th Italian Meeting on Mitochondrial Diseases. Owing to the ongoing situation with Covid-19, it will be organised as a virtual conference.

The meeting will bring together doctors, researchers and patients and will be a unique opportunity to discuss and update on current understandings of mitochondrial diseases and pathways towards diagnosis and treatment.

Mitochondrial diseases are very complex disorders little known by the scientific community itself until a few years ago. In recent years, giant steps have been taken in the study of the basic mechanisms involved in these diseases and we have finally moved from the diagnosis to the study of possible treatments.

Since its first edition in 2011, the annual Italian Meeting on Mitochondrial Diseases has contributed to this process by gathering the entire community of Italian doctors and researchers around the association of patients and helping to strengthen international partnerships and collaborations, making the whole community grow together and contributing to sharing knowledge and research progress.

The program, drawn up in collaboration with Mitocon’s Scientific Committee, has been designed to inspire the integration of technology and innovation into medical practice. In addition to the natural history of diseases and pre-clinical models, we will talk about the “high tech” involvement in mitochondrial medicine, robotics and gene therapy.

A very important session will be dedicated to the research of therapies, with a specific focus on an update on current clinical trials. It will be a unique opportunity for discussion between clinicians and industry and a real possibility for new collaborations.

This 10th edition of the meeting is dedicated to one of the fathers of mitochondrial medicine, Prof. Salvatore Di Mauro, for decades leading one of the first and main research groups on mitochondria at Columbia University in NY (US), which has attracted and built entire generations of mitochondriologists in Italy and worldwide. A special lecture will be dedicated to him for his 80 years.

The meeting will be in English to facilitate participation of doctors and researchers from all over the world, promoting international exchange and collaboration, crucial to fight together against mitochondrial diseases.

On October 9 the meeting will start at 9.30 am (Italian time) and close at 7.30 pm.

On October 10 it will start at 9 am (Italian time) and close at 1.30 pm.

Main topics:

  • Accelerating high tech involvement in daily practice
  • Current trials and industry
  • Gene therapy and editing
  • Mitochondrial diseases, natural history and cohorts
  • Pathophysiology and models of mitochondrial dysfunction

Scientific Faculty

Costanza Lamperti, Division of Medical Genetics and Neurogenetics, Mariani Foundation Center for the Study of Mitochondrial Pediatric
Diseases, Fondazione IRCCS Neurological Institute “C. Besta”, Milan

Enrico Bertini, Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Childrens’ Research Hospital, Rome

Massimiliano Filosto, ASST Spedali Civili, University of Brescia

Massimo Zeviani, Department of Neurosciences, University of Padua

Michelangelo Mancuso, AOUP, Neurological Institute, University of Pisa

Olimpia Musumeci, AOU Policlinico “G.Martino”, University of Messina

Serenella Servidei, Neurology Institute, Catholic University of the Sacred Heart, Rome

Valeria Tiranti, Fondazione IRCCS Neurological Institute “C. Besta”, Milan

Valerio Carelli, IRCCS Institute of Neurological Sciences (ISBN), Bellaria Hospital, Bologna


Confirmed speakers

Holger Prokisch, Technical University Munich

Costanza Lamperti, Fondazione IRCCS Istituto Neurologico “C. Besta”, Milan

Daniela Zuccarello, Department of Lab Medicine, Unit of Clinical Genetics and Epidemiology, University Hospital of Padua

Anu Suomalainen Wartiovaara, Department of Neurosciences, University of Helsinki

Matthew Klein, Global Head Gene and Mitochondrial Therapies, PTC Therapeutics

Magnus Hansson, Chief Medical Officer, Vice President Preclinical & Clinical Development, Abliva (ex Neurovive Pharmaceutical)

Aidan Gill, Head of Medical EU, Minovia

Magali Taiel, MD Chief Medical Officer, GenSight Biologics

Alejandro Dorenbaum, Chief Medical Officer, Reneo Pharmaceuticals

Jan Smeitink, CEO Khondrion

Carlos T. Moraes, University of Miami Miller School of Medicine

Carlo Viscomi, Department of Biomedical Sciences, University of Padua

Ramon Martí, Research group on neuromuscular and mitochondrial diseases, Vall d’Hebron Research Institute (VHIR), Barcelona, Catalonia

B. Y. Mok, Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA (USA)

Michelangelo Mancuso, AOUP, Neurological Institute, University of Pisa

Thomas Klopstock, Department of Neurology, University of Munich, Germany

Robert MacFarland, Wellcome Trust Centre for Mitochondrial Research, UK

Diego Martinelli, Genetics and Rare Diseases Research Division, Unit of Metabolism, Bambino Gesù Children’s Research Hospital, Rome

Vania Broccoli, CNR – National Research Council, Institute of Neuroscience, Milan

L. Scorrano, Department of Biology & VIMM, University of Padua


Mitocon is an association of patients affected by mitochondrial diseases and their families striving to advance research towards a cure. Encouraging collaboration and the exchange of knowledge within the scientific community is our priority. For this reason, participation in this meeting is free, but we would be grateful if you could support our commitment and work with a donation.